Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
1.
J Intern Med ; 282(4): 284-297, 2017 10.
Article in English | MEDLINE | ID: mdl-28649750

ABSTRACT

Vasopressin (AVP) plays a major role in the regulation of water and sodium homeostasis by its antidiuretic action on the kidney, mediated by V2 receptors. AVP secretion is stimulated by a rise in plasma osmolality, a decline in blood volume or stress. V1a receptors are expressed in vascular smooth muscle cells, but the role of vasopressin in blood pressure regulation is still a matter of debate. AVP may also play a role in some metabolic pathways, including gluconeogenesis, through its action on V1a receptors expressed in the liver. It is now understood that thirst and arginine vasopressin (AVP) release are regulated not only by the classical homeostatic, intero-sensory plasma osmolality negative feedback, but also by novel, extero-sensory, anticipatory signals. AVP measurement is time-consuming, and AVP level in the blood in the physiological range is often below the detection limit of the assays. Recently, an immunoassay has been developed for the measurement of copeptin, a fragment of the pre-provasopressin molecule that is easier to measure. It has been shown to be a good surrogate marker of AVP.


Subject(s)
Osmoregulation/physiology , Vasopressins/physiology , Animals , Drinking/physiology , Eating/physiology , Glycopeptides/blood , Glycopeptides/physiology , Humans , Islets of Langerhans/physiology , Kidney/physiology , Liver/physiology , Receptors, Vasopressin/physiology , Thirst/physiology
2.
Best Pract Res Clin Endocrinol Metab ; 30(2): 235-47, 2016 03.
Article in English | MEDLINE | ID: mdl-27156761

ABSTRACT

Copeptin is part of the 164 amino acid precursor protein preprovasopressin together with vasopressin and neurophysin II. During precursor processing, copeptin is released together with vasopressin. Copeptin concentrations respond as rapidly as vasopressin to changes in osmolality, a decrease in blood pressure or stress and there is a close correlation of vasopressin and copeptin concentrations. For these reasons, copeptin is propagated as a surrogate marker for vasopressin in the differential diagnosis of the polyuria-polydipsia syndromes and hyponatremia. Results of prospective studies show that a baseline copeptin level without prior fluid deprivation >20 pmol/L is able to identify patients with nephrogenic diabetes insipidus, whereas osmotically stimulated copeptin levels differentiate between patients with partial central diabetes insipidus and primary polydipsia with a high sensitivity and specificity >94%. In hyponatremia, low copeptin levels point to primary polydipsia and high levels to hypovolemic hyponatremia. The copeptin to urinary sodium ratio differentiates accurately between volume-depleted and normovolemic disorders.


Subject(s)
Glycopeptides/blood , Hyponatremia/blood , Polydipsia/blood , Polyuria/blood , Biomarkers/blood , Humans , Hyponatremia/pathology
3.
Clin Endocrinol (Oxf) ; 82(4): 570-6, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25200793

ABSTRACT

OBJECTIVE: To study the interaction between copeptin and hypothalamic-pituitary-adrenal (HPA) activation in men and women during hypoglycaemic stress. DESIGN AND PATIENTS: A prospective study in 118 patients (mean age 47·7 ± 13·6 years, n = 52 women) undergoing insulin tolerance testing for suspected pituitary dysfunction. MEASUREMENTS: Serum copeptin was measured in serially collected blood samples and assessed in relation to ACTH, cortisol and other endocrine parameters. RESULTS: Symptomatic hypoglycaemia (mean glucose nadir, 1·6 ± 0·5 mmol/l) resulted in a rapid significant increase of serum copeptin. Individuals with impaired pituitary function had lower stress-induced copeptin levels (median, 6·26 pmol/l) than patients with intact pituitary (8·46 pmol/l, P < 0·001). A weak overall correlation between stress-induced copeptin and cortisol levels was observed (rs  = 0·31, P < 0·001). In female individuals, there was a positive correlation between stress-induced copeptin and ACTH (rs  = 0·47, P < 0·001) or cortisol levels (rs  = 0·42, P = 0·002), while in males, no correlation with ACTH levels (rs  = 0·03, P = 0·75) and poor correlation with cortisol levels (rs  = 0·24, P = 0·045) was observed. Patients with central diabetes insipidus showed lowest baseline (2·20 pmol/l) and stimulated copeptin levels (3·68 pmol/l). CONCLUSIONS: The data from this study indicate that stress-induced release of AVP in women, but not in men, is linked to the co-activation of the hypothalamic-pituitary-adrenal system.


Subject(s)
Arginine Vasopressin/blood , Hypothalamo-Hypophyseal System/physiology , Pituitary-Adrenal System/physiology , Stress, Physiological , Adrenocorticotropic Hormone/blood , Adult , Blood Glucose/analysis , Corticotropin-Releasing Hormone/blood , Female , Glucose Tolerance Test , Glycopeptides/blood , Glycopeptides/metabolism , Humans , Hydrocortisone/blood , Hypoglycemia/blood , Hypoglycemia/genetics , Insulin , Male , Middle Aged , Pituitary Gland/metabolism , Prospective Studies , Sex Factors
4.
Int J Obes (Lond) ; 37(4): 598-603, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22614056

ABSTRACT

BACKGROUND: High plasma copeptin (copeptin), the C-terminal fragment of arginine vasopressin pro-hormone, has been associated with the metabolic syndrome (MetS), diabetes mellitus (DM) development and nephropathy. Here we tested whether elevated copeptin level is associated with later development of the MetS, its individual components and microalbuminuria. METHODS: We analysed copeptin at baseline (1991-1994) in the population-based Malmö Diet and Cancer Study cardiovasular cohort and re-examined 2064 subjects 15.8 years later (mean age 72.8 years, 59% women) with oral glucose tolerance test and measurement of MetS and its individual components. RESULTS: After age and sex adjustment, increasing quartiles of copeptin at baseline (the lowest quartile as reference) were associated with MetS (P for trend=0.008), incident abdominal obesity (P for trend=0.002), DM (P for trend=0.001) and microalbuminuria (P for trend=0.002). After additional adjustment for all the MetS components at baseline, increasing copeptin quartiles predicted incident abdominal obesity (odds ratios 1.55, 1.30 and 1.59; P for trend=0.04), DM (odds ratios 1.18, 1.32 and 1.46; P for trend=0.04) and microalbuminuria (odds ratios 1.05, 1.08 and 1.65; P for trend=0.02) but not MetS (P for trend=0.19) at the reexamination. Further, the relationship between copeptin and microalbuminuria was independent of baseline C-reactive protein, incident DM and incident hypertension. CONCLUSION: Copeptin independently predicts DM and abdominal obesity but not the cluster of MetS. Apart from predicting DM and abdominal obesity, elevated copeptin signals increased risk of microalbuminuria. Interestingly, the association between copeptin and later microalbuminuria was independent of both prevalent and incident DM and hypertension. Our findings suggest a relationship between a dysregulated vasopressin system and cardiometabolic risk, which could have implications for risk assessment and novel preventive treatments.


Subject(s)
Albuminuria/metabolism , Arginine Vasopressin/metabolism , Cardiovascular Diseases/metabolism , Diabetes Mellitus/metabolism , Glycopeptides/metabolism , Metabolic Syndrome/metabolism , Neoplasms/metabolism , Obesity, Abdominal/metabolism , Age Distribution , Age of Onset , Aged , Aged, 80 and over , Albuminuria/epidemiology , Biomarkers/metabolism , C-Reactive Protein/metabolism , Cardiovascular Diseases/epidemiology , Diabetes Mellitus/epidemiology , Female , Humans , Longitudinal Studies , Male , Metabolic Syndrome/epidemiology , Middle Aged , Neoplasms/epidemiology , Obesity, Abdominal/epidemiology , Predictive Value of Tests , Prevalence , Prospective Studies , Risk Factors , Sex Distribution , Sweden/epidemiology , Time Factors
5.
J Intern Med ; 272(5): 484-91, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22530956

ABSTRACT

OBJECTIVES: A number of inflammatory biomarkers such as C-reactive protein (CRP) are independent predictors of cardiovascular risk. The inflammatory biomarker procalcitonin (PCT) has previously been shown to be associated with coronary atherosclerosis and the metabolic syndrome. We evaluated the ability of PCT to predict future cardiovascular events in a population of apparently healthy individuals. DESIGN: We measured plasma PCT levels in 3713 subjects with no previous history of cardiovascular disease, randomly selected from the Malmö Diet and Cancer cohort. The correlation between PCT concentration and the incidence of coronary events, stroke and cardiovascular death over a median follow-up period of 13.7 years was studied using a Cox regression analysis corrected for age, sex, CRP level, traditional risk factors and renal function. RESULTS: Age and sex were strong determinants of PCT; the concentration of PCT was significantly higher in men than in women. PCT was associated with several of the established cardiovascular risk factors (CRP, hypertension, diabetes and renal function) as determined by multivariate linear regression. Of note, PCT was inversely correlated with HDL and smoking. We found significant correlations between PCT levels, coronary events and cardiovascular death. However, these relationships lost statistical significance when the analysis was corrected for CRP and the traditional risk factors. CONCLUSIONS: This is the largest population-based prospective study to demonstrate a positive association between plasma PCT levels and cardiovascular risk in subjects with no previous history of acute cardiovascular events. However, the high degree of covariation between PCT and other cardiovascular risk factors limits the value of PCT as an independent cardiovascular risk predictor.


Subject(s)
C-Reactive Protein/metabolism , Calcitonin/blood , Cardiovascular Diseases/blood , Protein Precursors/blood , Aged , Biomarkers/blood , Biomarkers/metabolism , Calcitonin Gene-Related Peptide , Cardiovascular Diseases/mortality , Female , Humans , Male , Middle Aged , Prospective Studies , Regression Analysis , Risk Factors
6.
Neurology ; 76(6): 563-6, 2011 Feb 08.
Article in English | MEDLINE | ID: mdl-21228295

ABSTRACT

BACKGROUND: TIA is a strong predictor of subsequent stroke. The hypothalamic stress hormone copeptin is an accurate prognostic marker in acute ischemic stroke. This study assessed prognostic reliability of 2 distinct stress hormones, copeptin and cortisol, for the risk stratification of re-events in patients with TIA. METHODS: We conducted a prospective study in patients admitted to the emergency department with a TIA. Clinical risk scoring using the ABCD2 score was determined and both hormones were measured in plasma on admission. The primary endpoint was a cerebrovascular re-event within 90 days. RESULTS: We included 107 consecutive patients with TIA. Re-events occurred in 10 patients (9%). Copeptin levels were higher in patients with a re-event compared with patients without re-event (p = 0.02), in contrast to cortisol (p = 0.53). Copeptin revealed a higher area under the receiver operating characteristics curve (AUC) to predict re-events compared to the ABCD2 score (AUC of 0.73 vs 0.43; p < 0.01) and improved its prognostic accuracy (AUC of combined model of 0.77; p = 0.002). CONCLUSION: Measurement of plasma copeptin but not cortisol levels in patients with TIA provides additional prognostic information beyond the ABCD2 clinical risk score alone. If confirmed in future studies, routine copeptin measurement may be an additional tool for risk stratification and targeted resource allocation after TIA.


Subject(s)
Glycopeptides/blood , Hydrocortisone/blood , Ischemic Attack, Transient/blood , Stroke/blood , Aged , Biomarkers/blood , Cerebrovascular Disorders/blood , Cerebrovascular Disorders/diagnosis , Cerebrovascular Disorders/prevention & control , Cohort Studies , Female , Humans , Ischemic Attack, Transient/complications , Ischemic Attack, Transient/diagnosis , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Risk Factors , Secondary Prevention , Stroke/diagnosis , Stroke/prevention & control
7.
J Hum Hypertens ; 25(2): 106-13, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20182452

ABSTRACT

Endothelin-1 (ET-1), a circulating vasoactive peptide with potent vasoconstricting and mitogenic properties, may contribute to target-organ damage in hypertension. We investigated whether plasma levels of C-terminal pro-endothelin-1 (CT-pro-ET-1) are associated with left ventricular (LV) mass and aortic root diameter in African-American adults with hypertension. Plasma CT-pro-ET-1 was measured by an immunoluminometric assay in 1041 African Americans (65±9 years, 72% women) with hypertension. LV mass and aortic root diameter were measured according to the American Society of Echocardiography guidelines, and LV mass was indexed by height to the power 2.7 (LVMi). Multivariable regression analyses were used to assess whether plasma CT-pro-ET-1 was associated with LVMi and aortic root diameter, independent of potential confounding variables. Plasma CT-pro-ET-1 was modestly correlated with LVMi (r=0.21, P<0.0001) and aortic root diameter (r=0.09, P=0.004). In separate multivariable regression models that adjusted for age, sex, body mass index, total and high-density lipoprotein cholesterol, smoking history, diabetes, history of myocardial infarction or stroke, and blood pressure-lowering medication and statin use, log CT-pro-ET-1 was significantly associated with greater LVMi (P=0.001) and larger aortic root diameter (P=0.006). CT-pro-ET-1 is independently associated with LVMi and aortic root diameter and may be a marker of target-organ damage in African-Americans adults with hypertension.


Subject(s)
Aortic Valve/physiopathology , Endothelin-1/blood , Heart Ventricles/physiopathology , Hypertension , Hypertrophy, Left Ventricular/blood , Luminescent Measurements/methods , Peptide Fragments/blood , Black or African American , Aged , Aortic Valve/diagnostic imaging , Aortic Valve/pathology , Biomarkers , Confounding Factors, Epidemiologic , Echocardiography, Doppler , Female , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , Humans , Hypertension/blood , Hypertension/complications , Hypertension/epidemiology , Hypertension/physiopathology , Hypertrophy, Left Ventricular/diagnostic imaging , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/physiopathology , Male , Middle Aged , Regression Analysis , Risk Factors , United States/epidemiology
8.
Clin Pharmacol Ther ; 87(6): 686-92, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20445533

ABSTRACT

Inhibition of the renin-angiotensin system (RAS) improves hemodynamics and may ameliorate oxidative stress in heart failure (HF). Through activation of nicotinamide adenine dinucleotide phosphate oxidase, angiotensin II induces superoxide, which is primarily cleared by cytosolic copper-zinc superoxide dismutase (Cu/Zn-SOD). We examined the interdependency of hemodynamics and levels of Cu/Zn-SOD and oxidized low-density lipoprotein (oxLDL) in HF patients, using a randomized, double-blinded, crossover design to compare (i) the outcomes of single-agent therapy with either benazepril or valsartan alone vs. the combination thereof and (ii) the outcome of single-agent treatment with benazepril vs. single-agent treatment with valsartan. After each treatment, arterial (ART) and coronary sinus (CS) blood samples were collected. Cu/Zn-SOD and oxLDL levels were higher in CS samples than in ART samples. Furthermore, patients under combined treatment exhibited the highest CS levels of Cu/Zn-SOD, whereas there was no significant difference between the groups on either benazepril or valsartan alone. This finding suggests an augmentation of the cardiac antioxidative potential under more complete RAS inhibition. Cu/Zn-SOD and oxLDL levels correlated with measures of afterload rather than preload, which in turn suggests a beneficial effect of afterload reduction on oxidative stress in HF.


Subject(s)
Benzazepines/pharmacology , Heart Failure/drug therapy , Renin-Angiotensin System/drug effects , Superoxide Dismutase/drug effects , Tetrazoles/pharmacology , Valine/analogs & derivatives , Adult , Aged , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin II Type 1 Receptor Blockers/pharmacology , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Benzazepines/administration & dosage , Cross-Over Studies , Double-Blind Method , Drug Therapy, Combination , Female , Heart Failure/physiopathology , Hemodynamics/drug effects , Humans , Lipoproteins, LDL/drug effects , Lipoproteins, LDL/metabolism , Male , Middle Aged , Oxidative Stress/drug effects , Superoxide Dismutase/metabolism , Tetrazoles/administration & dosage , Valine/administration & dosage , Valine/pharmacology , Valsartan
9.
Minerva Anestesiol ; 76(11): 905-12, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20386508

ABSTRACT

BACKGROUND: Plasma copeptin levels before and during exogenous arginine vasopressin infusion (AVP) were evaluated, and the value of copeptin levels before AVP therapy to predict complications during AVP therapy and outcome in vasodilatory shock patients was determined. METHODS: This prospective, observational study was nested in a randomized, controlled trial investigating the effects of two AVP doses (0.033 vs. 0.067 IU/min) on the hemodynamic response in patients with advanced vasodilatory shock due to sepsis, systemic inflammatory response syndrome or after cardiac surgery. Clinical data, plasma copeptin levels and adverse events were recorded before, 24 hours after and 48 hours after randomization. RESULTS: Plasma copeptin levels were elevated before AVP therapy. During AVP, copeptin levels decreased (P<0.001) in both groups (P=0.73). Copeptin levels at randomization predicted the occurrence of ischemic skin lesions (AUC ROC, 0.73; P=0.04), a fall in platelet count (AUC ROC, 0.75; P=0.01) during AVP and intensive care unit mortality (AUC ROC, 0.67; P=0.04). Twenty-five patients (64.1%) exhibited a decrease in copeptin levels. Patients experiencing a decrease in copeptin levels were older (P=0.04), had a higher Sequential Organ Failure Assessment score count before (P=0.03) and during AVP therapy (P=0.04), had a longer intensive care unit stay (P<0.001) and required AVP therapy longer (P=0.008) than patients without a decrease in copeptin levels during AVP. CONCLUSION: Plasma copeptin levels are elevated in patients with advanced vasodilatory shock. During exogenous AVP therapy, copeptin levels decrease, suggesting suppression of the endogenous AVP system.


Subject(s)
Arginine Vasopressin/therapeutic use , Glycopeptides/blood , Shock/drug therapy , Aged , Arginine Vasopressin/administration & dosage , Critical Illness , Endpoint Determination , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Prospective Studies , Shock/physiopathology , Treatment Outcome , Vasodilation/physiology
10.
Acta Neurochir Suppl ; 106: 221-4, 2010.
Article in English | MEDLINE | ID: mdl-19812953

ABSTRACT

The incidence of water and electrolyte disturbances following traumatic brain injury (TBI) is considerable and has been attributed to a dysregulation of the hypothalamic peptide arginine-vasopressin (AVP). Copeptin, the C-terminal part of the AVP prohormone, reflects AVP activity. In 71 TBI patients we measured copeptin in serum by a sandwich immunoassay. Injury severity was assessed by Glasgow Coma Score (GCS) and computed tomography, and recovery by Glasgow Outcome Score (GOS). Neuroendocrine and osmoregulation regulation were examined on day 0, 3 and 7, and 24 months post-injury. Copeptin was highest on admission (40.0 +/- 72.3 pmol/l), stabilized on day 3 and 7 (21.2 +/- 18.3 resp. 20.3 +/- 17.1 pmol/l), and normalized at follow-up (4.2 +/- 1.7 pmol/l). On admission, there was a correlation between serum sodium and urine excretion (p = 0.003), but the correlation got lost on day 3 and 7. Copeptin did not reflect the individual 24 h urine excretion or serum sodium levels indicating an uncoupling of copeptin/AVP release and renal water excretion. High copeptin level on day 3 were correlated with a low GCS (p < 0.001), midline shift (p = 0.019), intracerebral hemorrhage (p = 0.026), SAPS score (p = 0.001), as well as with a low GOS (p = 0.031). Copeptin was significantly decreased following skullbase fracture (p = 0.016).Our data reveal a loss of hypothalamic osmoregulation following TBI. The measurement of Copeptin/AVP release reveals a significant predictive function for the severity of TBI.


Subject(s)
Brain Injuries/blood , Glycopeptides/blood , Water-Electrolyte Balance/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Glasgow Coma Scale , Humans , Male , Middle Aged , Sodium/blood , Time Factors , Young Adult
11.
J Intern Med ; 267(1): 119-29, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19570053

ABSTRACT

OBJECTIVES: The concentration of atrial natriuretic peptide (ANP) in the circulation is approximately 10- to 50- fold higher than B-type natriuretic peptide (BNP). We sought to compare the accuracy of midregional pro-atrial natriuretic peptide (MRproANP) measured with a novel sandwich immunoassay with N-terminal pro-B-type natriuretic peptide (NTproBNP) in the diagnosis of heart failure. DESIGN: The diagnosis of heart failure was adjudicated by two independent cardiologists using all available clinical data (including BNP levels) in 287 consecutive patients presenting with dyspnoea to the emergency department (ED). MRproANP and NTproBNP levels were determined at presentation in a blinded fashion. RESULTS: Heart failure was the adjudicated final diagnosis in 154 patients (54%). Median MRproANP was significantly higher in patients with heart failure as compared to patients with other causes of dyspnoea (400 vs. 92 pmol L(-1), P < 0.001). The diagnostic accuracy of MRproANP was very high with an area under the receiver operating characteristic curve of 0.92 and was comparable with that of NTproBNP (0.92, P = 0.791). Moreover, MRproANP provided incremental diagnostic information to BNP and NTproBNP in patients presenting with BNP levels in the grey zone between 100 and 500 pg mL(-1). CONCLUSION: Midregional pro-atrial natriuretic peptide is as accurate in the diagnosis of heart failure as NTproBNP. MRproANP seems to provide incremental information on top of BNP or NT-proBNP in some subgroups and should be further investigated in other studies.


Subject(s)
Atrial Natriuretic Factor/blood , Heart Failure/diagnosis , Natriuretic Peptide, Brain/blood , Peptide Fragments/blood , Aged , Biomarkers/blood , Dyspnea/diagnosis , Dyspnea/etiology , Female , Humans , Male , Predictive Value of Tests , Prospective Studies , ROC Curve , Risk Factors , Survival Rate
12.
Horm Metab Res ; 41(6): 430-5, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19513951

ABSTRACT

Genotypes of the T393C SNP of GNAS1, a gene that encodes for the Galphas subunit of G proteins have been significantly associated with the clinical course in a variety of cancers. Since this SNP may also influence the course of Graves' disease (GD) and, especially, Graves' ophthalmopathy (GO), we determined genotype and allele frequency in a series of 359 patients, which were referred to our clinic within 6 months of the onset of GO. Among them, 336 patients also suffered from associated hyperthyroidism. Data on relapse and remission rates 12 months after termination of a 1 year antithyroid drug therapy was available for 276 patients. As controls, 820 healthy individuals were recruited. Our data suggest that the T393C SNP does not represent a risk factor for the development of both GD and GO. It was, however, significantly associated with the course of hyperthyroidism (p=0.013) and a similar trend was evident for the course of GO (p=0.093). Homozygous TT carriers showed a significantly increased risk (p=0.03) for hyperthyroidism to relapse (OR 2.4; 95% CI 1.1-5.4). Also, the TT genotype was associated with significantly increased serum TRAb levels (CC+CT: 5.4 IU/l vs. TT: 9.3 IU/l). This is probably caused by increased G-Protein susceptibility to TSHR-mediated stimulation through TRAb. Genotyping of the T393C SNP of GNAS1 may become a useful additional tool to predict the clinical course of GD and GO. This may allow the clinician to identify patients at risk for more severe courses of disease and to come to more timely decisions for treatment.


Subject(s)
GTP-Binding Protein alpha Subunits, Gs/genetics , Graves Disease/genetics , Polymorphism, Single Nucleotide , Chromogranins , Cohort Studies , Female , Graves Disease/drug therapy , Graves Ophthalmopathy/drug therapy , Graves Ophthalmopathy/genetics , Humans , Hyperthyroidism/drug therapy , Hyperthyroidism/genetics , Male
13.
Diabetologia ; 52(7): 1343-51, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19415232

ABSTRACT

AIMS/HYPOTHESIS: Evolving research suggests that common and rare alleles jointly constitute the genetic landscape of complex disease. We studied the association between 43 pathway-related candidate genes with 'intermediate phenotype' (i.e. corresponding plasma protein) and diabetic nephropathy in a customised microarray of 1,536 SNPs. METHODS: In this case-control study of type 2 diabetic Chinese individuals with and without diabetic nephropathy, cases (n = 545) were defined on the basis of a spot urinary albumin/creatinine ratio (ACR) > 113 mg/mmol; the value for controls (n = 503) was ACR < 3.3 mg/mmol. Genotyping was performed using Illumina GoldenGate assay. RESULTS: No single nucleotide polymorphism (SNP) remained significant in single locus analysis after correction for multiple testing. Therefore, we explored the best approximately 1% SNPs. Of these 13 SNPs, four clustered to a 5' end NADPH oxidase homologue 4 (NOX4) haplotype (GGCC frequency = 0.776) with estimated OR for diabetic nephropathy of 2.05 (95% CI 1.04-4.06) (heterozygous) and 2.48 (1.27-4.83) (homozygous) (p = 0.0055). The haplotype was correlated with plasma Cu/Zn superoxide dismutase (SOD) concentration, suggesting increased oxidative burden. Endothelin-1 SNP (rs1476046G>A, frequency = 0.252) was correlated with plasma C-terminal pro-endothelin-1 concentrations with an estimated OR for diabetic nephropathy of (heterozygous) 1.26 (0.96-1.66) and (homozygous) 1.87 (1.13-3.12) (p = 0.0072). Nitric oxide synthase 1 (NOS1) 5' haplotype (TGTC frequency = 0.38) also revealed a suggestive association with diabetic nephropathy: heterozygous 1.26 (0.95-1.67), homozygous 1.57 (1.04-2.35) (p = 0.0073). A rare NADPH oxidase homologue 1 (NOX1)-coding non-synonymous SNP (Arg315His, frequency = 0.006) was found exclusively among cases. CONCLUSIONS/INTERPRETATION: Our preliminary observations suggest that common haplotypes from NOX4 and endothelin-1 SNP correlated with plasma Cu/Zn SOD and C-terminal pro-endothelin-1 concentrations, respectively, and might have conferred diabetic nephropathy susceptibility. Common NOS1 and rare NOX1 variants also revealed a suggestive association with diabetic nephropathy. Future studies to validate our observation are needed.


Subject(s)
Asian People/genetics , Diabetes Mellitus, Type 2/genetics , Diabetic Nephropathies/genetics , Endothelin-1/genetics , NADPH Oxidases/genetics , Nitric Oxide Synthase Type I/genetics , Aged , Blood Proteins/genetics , Case-Control Studies , Diabetes Mellitus, Type 2/ethnology , Diabetic Nephropathies/ethnology , Female , Genetic Predisposition to Disease/ethnology , Haplotypes , Humans , Male , Middle Aged , NADPH Oxidase 4 , Oligonucleotide Array Sequence Analysis , Polymorphism, Single Nucleotide , Singapore/epidemiology
14.
Heart ; 95(15): 1258-64, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19414437

ABSTRACT

OBJECTIVE: To explore the morphological and functional effect of selective and non-selective endothelin (ET)-receptor blockade in coronary artery disease (CAD). DESIGN: Prospective randomised controlled trial. SETTING: University hospital. PATIENTS: 26 patients with stable CAD. INTERVENTIONS: Intracoronary infusion (30 minutes) of the ET-A receptor blocker BQ-123 (40 nmol/min, group A, n = 13) alone or with the ET-B receptor blocker BQ-788 (10 nmol/min, group AB, n = 13) as well. MAIN OUTCOME MEASURES: Fractional flow reserve (FFR), coronary flow reserve (CFR) and intramyocardial resistance (IMR) by PressureWire, mean arterial blood pressure (MAP), minimal lumen diameter (MLD) and average angiographic lumen diameter (mean LD) of the target vessel before and after intracoronary infusion of ET antagonists. Concentrations of C-terminal pro-endothelin-1 (CT-proET1) in arterial blood were determined before and after infusion. RESULTS: Mean MLD, mean LD, FFR, CFR, IMR and MAP remained unaffected by ET-receptor blockade in both groups; their changes were comparable. Concentrations of CT-proET-1 increased by 6.2 (SD 5.9) pmol/l (95% CI 1.2 to 11.1 pmol/l; p = 0.022) in group A and by 4.1 (SD 4.3) pmol/l (95% CI 1.1 to 7.2 pmol/l; p = 0.014) in group AB. CONCLUSIONS: We found a broad variety of individual haemodynamic responses to ET-receptor antagonists with an overall neutral effect after an infusion period of 30 minutes despite an overall effective blockade of ET-receptors. Prolonged infusion time may be needed to cause a more distinct vasomotor response. TRIAL REGISTRATION NUMBER: NCT00427232.


Subject(s)
Antihypertensive Agents/therapeutic use , Coronary Artery Disease/drug therapy , Endothelin Receptor Antagonists , Oligopeptides/therapeutic use , Peptides, Cyclic/therapeutic use , Piperidines/therapeutic use , Adult , Aged , Angina Pectoris/drug therapy , Angina Pectoris/physiopathology , Coronary Angiography , Coronary Artery Disease/blood , Coronary Artery Disease/physiopathology , Endothelin-1/blood , Female , Fractional Flow Reserve, Myocardial/drug effects , Humans , Male , Middle Aged , Myocardial Ischemia/drug therapy , Myocardial Ischemia/physiopathology , Prospective Studies , Protein Precursors/blood , Young Adult
15.
Br J Ophthalmol ; 93(8): 1052-6, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19221109

ABSTRACT

BACKGROUND AND AIMS: Retrospective, observational study to compare clinical symptoms and TSH-receptor antibodies (TRAb) in Graves ophthalmopathy (GO) in euthyroid and primarily hypothyroid patients to those in hyperthyroid patients. METHODS: Clinical symptoms (NOSPECS (severity) and CAS (activity) score), prevalence and levels of thyroid specific antibodies and the course of the disease were evaluated in 143 primarily hyperthyroid, 28 primarily euthyroid and 11 primarily hypothyroid patients with GO. RESULTS: Patients with euthyroid/hypothyroid GO developed significantly less severe GO symptoms (NOSPECS score 4.4 vs 5.7; p = 0.03), less active GO (CAS score 3.9 vs 5.2; p = 0.002) and more asymmetrical disease (proptosis side difference: 1.9 mm vs 1.0 mm (p = 0.01); side difference of > or = 3 mm: 23% vs 4.8%) than hyperthyroid patients. TRAb levels 6 months after GO onset were significantly lower (2.2 IU/l, p = 0.02) in euthyroid/hypothyroid than in hyperthyroid patients (8.6 IU/l), as was the prevalence of both TRAb and thyroid peroxidase antibodies (75% vs 94.6%, p = 0.0008). CONCLUSIONS: The knowledge about the phenotype of GO in primarily euthyroid and hypothyroid patients is helpful for differential diagnosis and patient consultation. TRAb titres are very low in these patients, and the availability of a sensitive assay technique is therefore an important diagnostic tool in euthyroid and hypothyroid patients.


Subject(s)
Graves Ophthalmopathy/complications , Hypothyroidism/complications , Adult , Aged , Aged, 80 and over , Autoantibodies/blood , Female , Graves Ophthalmopathy/immunology , Graves Ophthalmopathy/pathology , Humans , Hypothyroidism/immunology , Hypothyroidism/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Receptors, Thyrotropin/immunology , Retrospective Studies , Severity of Illness Index , Thyroid Gland/immunology , Thyroid Gland/pathology , Young Adult
16.
Inflamm Res ; 58(6): 298-305, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19212702

ABSTRACT

BACKGROUND: Adrenomedullin (ADM) and endothelin-1 (ET-1) are novel promising peptide biomarkers in chronic heart failure (CHF). According to recent studies among their pleiotropic effect they play roles in the regulation of inflammation. The aim of the study was to measure the above mentioned two vasoactive peptides in parallel in a well characterized population of patients with CHF, and study their associations with inflammatory markers. MATERIALS AND METHODS: A total of 186 patients (138 male, 48 female) with <45% left ventricular ejection fraction (LVEF), and without acute inflammatory disease, were enrolled. Plasma midregional-proADM (MR-proADM) and C-terminal-proET-1 (CT-proET-1) were determined by a novel sandwich immunoluminometric assay. RESULTS: Increased MR-proADM and CT-proET-1 plasma levels were measured in patients with severe CHF (NYHA III-IV) as compared to the group of NYHA I-II (p<0.0001). MR-proADM and CT-proET-1 levels showed significant negative correlation with serum albumin and prealbumin levels (p

Subject(s)
Adrenomedullin/metabolism , Endothelin-1/metabolism , Heart Failure/metabolism , Ventricular Dysfunction, Left/metabolism , Aged , Biomarkers/metabolism , Chronic Disease , Cross-Sectional Studies , Female , Humans , Inflammation/metabolism , Male , Middle Aged
17.
J Intern Med ; 265(5): 604-15, 2009 May.
Article in English | MEDLINE | ID: mdl-19226375

ABSTRACT

OBJECTIVE: To assess the utility of B-type natriuretic peptide (BNP) and C-terminal-pro-endothelin-1 (CT-proET-1) to predict a severely impaired peak oxygen consumption (peak VO(2), < 14 mL kg(-1) min(-1)) in patients referred for cardiopulmonary exercise testing. DESIGN: Cross-sectional study. SETTING: Tertiary care center. METHODS: Peak VO(2), BNP and CT-proET-1 were assessed in 141 consecutive patients referred for cardiopulmonary exercise testing. RESULTS: B-type natriuretic peptide [median (interquartile range) 48 (38-319) vs. 33 (15-86) pg mL(-1); P = 0.002] and CT-proET-1 [87 (76-95) vs. 60 (52-74) pmol L(-1); P < 0.001] were higher in patients with a peak VO(2) < 14 mL kg(-1) min(-1) (n = 30) than in those with a peak VO(2) > or = 14 mL kg(-1) min(-1) (n = 111). CT-pro-ET-1 had a higher area under the receiver-operator-characteristics curve (AUC) to predict a peak VO(2) < 14 mL kg(-1) min(-1) than BNP (0.79 vs. 0.68; P = 0.04). The optimal BNP cut-off of 37.2 pg mL(-1) had a sensitivity of 80% and a specificity of 56%. The optimal CT-proET-1 cut-off of 74.4 pmol L(-1) had a sensitivity of 80% and specificity of 76%. A five-item score composed of body mass index, diabetes, forced expiratory volume within the first second, alveolo-arterial oxygen pressure difference, and BNP had an AUC of 0.88 to predict a peak VO(2) < 14 mL kg(-1) min(-1). Adding CT-proET-1 to the score resulted in an AUC of 0.92. CONCLUSIONS: C-terminal-pro-endothelin-1 is superior to BNP for the prediction of a peak VO(2) < 14 mL kg(-1) min(-1) in patients referred for CPET. A score incorporating body mass index, diabetes status, spirometry, blood gases, BNP and CT-proET-1 improves the prediction of a peak VO(2) < 14 mL kg(-1) min(-1) based on single biomarkers.


Subject(s)
Cardiovascular Diseases/metabolism , Endothelin-1/blood , Natriuretic Peptide, Brain/blood , Oxygen Consumption , Peptide Fragments/blood , Protein Precursors/blood , Aged , Area Under Curve , Biomarkers/blood , Body Mass Index , Cardiovascular Diseases/blood , Cross-Sectional Studies , Diabetes Complications/blood , Exercise Test , Female , Forced Expiratory Volume , Humans , Male , Middle Aged , Oxygen/blood , Risk Assessment , Sensitivity and Specificity
18.
Exp Clin Endocrinol Diabetes ; 117(3): 99-106, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19085703

ABSTRACT

BACKGROUND: We evaluated insulin sensitivity and beta cell function in patients with chronic heart failure (CHF), and investigated a possible correlation of these metabolic parameters with specific biomarkers of heart failure. Additionally, we investigated the effects of two angiotensin receptor blockers (ARBs), namely telmisartan and candesartan, that were administered over a 5 month treatment period, as additional therapy to standard care. METHODS AND RESULTS: The study group consisted of 94 CHF patients. Insulin sensitivity (OGIS index) and insulin secretion parameters were investigated by frequently sampled oral glucose tolerance tests and consecutive mathematical modelling. In total, 94.6 % of patients had clinically overt diabetes, impaired glucose tolerance or insulin resistance at the time of enrolment HbA1c was found to correlate to NT-proBNP, MR-proADM, CT-proET-1, and MR-proANP, but not to Copeptin. NT-proBNP correlated inversely to OGIS. None of the metabolic parameters were altered significantly after candesartan or telmisartan treatment in either the patient or standard care group. CONCLUSION: Insulin sensitivity and insulin secretion are impaired in CHF and biomarkers of heart failure and atherosclerotic disease correlate to glucose metabolism.


Subject(s)
Blood Glucose/metabolism , Heart Failure/metabolism , Benzimidazoles/therapeutic use , Benzoates/therapeutic use , Biomarkers/blood , Biphenyl Compounds , Blood Pressure/drug effects , Chronic Disease , Heart Failure/complications , Heart Failure/drug therapy , Heart Failure/physiopathology , Humans , Lipid Metabolism/drug effects , Middle Aged , Obesity/complications , Telmisartan , Tetrazoles/therapeutic use
19.
Clin Endocrinol (Oxf) ; 67(4): 598-606, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17880406

ABSTRACT

OBJECTIVE: To assess the prevalence of hypopituitarism following traumatic brain injury (TBI), describe the time-course and assess the association with trauma-related parameters and early post-traumatic hormone alterations. DESIGN: A 12-month prospective study. PATIENTS: Forty-six consecutive patients with TBI (mild: N = 22; moderate: N = 9; severe: N = 15). MEASUREMENTS: Baseline and stimulated hormone concentrations were assessed in the early phase (0-12 days post-traumatically), and at 3, 6 and 12 months postinjury. Pituitary tests included the Synacthen-test (acute +6 months) and the insulin tolerance test (ITT) or the GHRH + arginine test if the ITT was contraindicated (3 + 12 months). Insufficiencies were confirmed by retesting. RESULTS: Early post-traumatic hormone alterations mimicking central hypogonadism or hypothyroidism were present in 35 of the 46 (76%) patients. Three months post-traumatically, 6 of the 46 patients failed anterior pituitary testing. At 12 months, one patient had recovered, whereas none developed new insufficiencies. All insufficient patients had GH deficiency (5 out of 46), followed by ACTH- (3 out of 46), TSH- (1 out of 46), LH/FSH- (1 out of 46) and ADH deficiency (1 out of 46). Hypopituitary patients had more frequently been exposed to severe TBI (4 out of 15) than to mild or moderate TBI (1 out of 31) (P = 0.02). Early endocrine alterations including lowered thyroid and gonadal hormones, and increased total cortisol, free cortisol and copeptin were positively associated to TBI severity (P < 0.05), but not to long-term development of hypopituitarism (P > 0.1), although it was indicative in some. CONCLUSION: Long-term hypopituitarism was frequent only in severe TBI. During the 3-12 months follow-up, recovery but no new insufficiencies were recorded, indicating manifest hypothalamic or pituitary damage already a few months postinjury. Very early hormone alterations were not associated to long-term post-traumatic hypopituitarism. Clinicians should, nonetheless, be aware of potential ACTH deficiency in the early post-traumatic period.


Subject(s)
Brain Injuries/complications , Hypopituitarism/etiology , Acute Disease , Adolescent , Adrenocorticotropic Hormone/deficiency , Adult , Brain Injuries/blood , Case-Control Studies , Female , Gonadotropins, Pituitary/deficiency , Growth Hormone/deficiency , Humans , Hypopituitarism/blood , Logistic Models , Male , Middle Aged , Odds Ratio , Pituitary Function Tests , Prospective Studies , Thyrotropin/deficiency , Time , Vasopressins/deficiency
20.
Horm Metab Res ; 39(1): 56-61, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17226115

ABSTRACT

BACKGROUND: Recently, we and others have demonstrated that high levels of auto-antibodies to the human TSH-receptor (TRAb) predict relapse of hyperthyroidism in Graves' disease (GD). Our objective was to extend the outcome of the prediction by combining TRAb with thyroperoxidase antibody (TPO-Ab) measurement. PATIENTS AND METHODS: One hundred and thirty-one GD patients (118 females, 13 males) were analysed, of whom 94 patients (71.8%) had relapse, whereas 37 (28.2%) went into remission. Second generation TRAb and TPO-Ab assays were performed in GD patients with relapse and remission in mean 4.3 months after initial diagnosis. RESULTS: The mean anti-TPO-Ab levels were similar in all patients with relapse and remission. However, there was a steady decline from 4047 U/ml to 530 U/ml in the remission group that correlated positively with TRAb values (>2 to >10 IU/l). The relapse group remained at consistently high levels. The positive predictive value (PPV) for relapse in patients with TRAbs >6 IU/l and anti-TPO-Abs >5000 U/ml was 100, whereas TRAbs >6 IU/l and anti-TPO-Abs >500 U/ml were associated with a PPV of 93.7 up to 96 (p=0.008). These Ab constellations accounted for about one third of all GD patients. For patients with TRAbs between >2 and <6 IU/l the PPV was 66.7-90.0. CONCLUSION: Our follow-up analysis indicates that the prediction of relapse of GD can be improved by a combined measurement of TRAb and TPO-Ab. In patients with moderately increased Abs, determined about 6 months after initial diagnosis, an ablative therapy can be approached without delay.


Subject(s)
Autoantibodies/analysis , Graves Disease/diagnosis , Iodide Peroxidase/immunology , Receptors, Thyrotropin/immunology , Thyrotoxicosis/diagnosis , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Prognosis , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...